Monitor for announcement of a permanent Chief Commercial Officer replacement and any impact on commercial execution for Akebia's products. The consulting transition suggests continuity, but the lack of a named successor introduces near-term uncertainty.
Price Chart
Executive Summary
Akebia Therapeutics disclosed the resignation of Nicholas Grund, Senior Vice President and Chief Commercial Officer, effective November 6, 2026, for personal reasons. He will transition to a consulting role through April 30, 2027, paid an hourly rate. This is a routine senior-level departure with a transition plan in place, no red flags.
Key Facts
- Nicholas Grund, SVP and Chief Commercial Officer, resigned effective November 6, 2026 for personal reasons.
- Grund entered a Consulting Agreement effective November 6, 2026 through April 30, 2027, paid an hourly rate.
- The consulting agreement can be terminated by the company with 10 days' notice or by Grund with 30 days' notice.
- No replacement for the Chief Commercial Officer role was announced.
Financial Impact
No material financial impact disclosed; consulting fees are hourly and not quantified.
Risk Factors
- Potential disruption to commercial operations if a permanent replacement is not named promptly.
- Loss of institutional knowledge from a departing senior commercial executive.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001517022-26-000071 |
| Document: 0001517022-26-000071-index-headers.html | 0001517022-26-000071 |
| Document: 0001517022-26-000071-index.html | 0001517022-26-000071 |
| Document: 0001517022-26-000071.txt | 0001517022-26-000071 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Press Release | $0.5765 | awaiting T+60 | — | $0.6593 (+14.36%) |
Oct 23, 2026 3d ago | 8-K | $0.5746 | awaiting T+60 | — | $0.6593 (−14.74%) |
Oct 14, 2026 13d ago | 8-K | $0.7020 | awaiting T+60 | — | $0.6593 (−6.08%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.9800 | awaiting T+60 | — | $0.6593 (−32.72%) |
Jun 30, 2026 17w ago | 8-K | $1.14 $0.9326 | ▼ −18.19% | ▼ −21.76% | $0.6593 (−42.17%) |
Apr 30, 2026 25w ago | Press Release | $1.40 | awaiting T+60 | — | $0.6593 (−52.91%) |
Feb 26, 2026 34w ago | 8-K | $1.32 $1.02 | ▼ −22.73% | ▼ −30.48% | $0.6593 (−50.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers